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SDiscussion
Dr R. Duane Davis (Durham, NC). Chris, my congratulations.
First of all, let me just put it in perspective. You are demonstrating
that it is sufficient to have anti-Gal to cause this injury and calci-The Journal of Thoracic and Ca
/Bfication, and therefore it does really raise the following question:
Can we have a better biologic valve? That is incredibly important.
You did game the system a little bit. We know that there are a lot
of non-Gal anti-swine or other antibodies present, and you did not
use those in this experiment. That has a lot of variability. It can be
as little as 5% of the anti-swine antibody, or it can be as high as
35%. What happens when you use those antibodies in this model?
Dr McGregor. Clearly there are multiple non-Gal antibodies,
as you say, of variable quantities, somewhere up to 20%. We
started by dealing with the major antibody, which was 80% of
the bulk. We had to start somewhere. Do non-Gal antibodies mat-
ter? I am sure they do, but I do not think that we have sufficiently
defined their specificity as of this time. The major effort in our lab-
oratory now is to identify and specify those non-Gal antibodies so
that we can eliminate them by further genetic alteration of the pig.
They are important, but they are probably at the 20% level, as you
say.
Dr Davis. Let me kind of follow this up in terms of—you have
this model, which obviously it is not putting it into the blood. Is
there a way that we can actually test this in vivo in an animal
model, or do we just need to go to human applications?
Dr McGregor. That is a wonderful and very important ques-
tion. The animal models are all flawed, and we have known it
for a long time. The rat model is simply the best we have. Over
40 years it has correlated not unreasonably with subsequent clini-
cal performance in terms of improvement of processing. The sheep
model, because of the Gal issue, of course, is not applicable.
We currently have a number of nonhuman primates with Gal-
positive and Gal-negative biological mitral valves in place. But
this study takes an extraordinary length of time, and I am not con-
vinced it is going to give us the answers because we might have to
run them for up to 10 years. The preponderance of evidence now is
so powerful that my own belief is that we should go to a clinical
trial in young patients using these Gal knockout tissues because
there is no downside and because the potential upside is so impor-
tant that I think the evidence suggests we should go ahead at this
time.
Dr Davis. I really could not agree with you more on that. The
aspect now that you know that there is non-Gal antibody—and
in this situation you do not need to necessarily have tissues that
have ongoing expression per se—are there ways that you can
manipulate these Gal knockout tissues to make them appear to
function better because of the other immunologic potential injuries
that they could have?
Dr McGregor. Clearly the amount of antigenic tissue in any
heart valve is in part determined by the intensity and durability
of pretreatment and also affected by the treatment that any recip-
ient would receive. Therefore in several of these studies, for exam-
ple, steroid therapy diminished the antigenicity. That is not
something we would want to do in patients, but I think with pro-
cessing, there are always going to be areas where we can improve
in terms of residual antigenicity. The question is this: Will we pay
a price chemically in terms of collagen cross-linking and so forth.rdiovascular Surgery c Volume 141, Number 1 275
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